Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) has announced it will host a conference call and live webcast on January 8, 2025, at 4:30 p.m. ET to provide a corporate update and discuss preliminary unaudited financial results for Q4 and full-year 2024. The webcast will be accessible through the company's investor relations website section at www.avadel.com, where it will remain archived for 90 days after the event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.

News Market Reaction – AVDL

+0.55%

+0.55% Session move

In the trading session that priced this news, AVDL gained 0.55%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.

A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:

Austin Murtagh
Precision AQ
Austin.Murtagh@precisionaq.com
(212) 698-8696

Media Contact:

Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162

FAQ

When will Avadel Pharmaceuticals (AVDL) release its Q4 and full-year 2024 preliminary results?

Avadel Pharmaceuticals will release its Q4 and full-year 2024 preliminary results on January 8, 2025, during a conference call and webcast at 4:30 p.m. ET.

How can investors access AVDL's Q4 2024 earnings conference call?

Investors can access the conference call by registering through the company's website, www.avadel.com, in the investor relations section. Registration should be completed at least 10 minutes before the call.

How long will AVDL's Q4 2024 earnings webcast be available for replay?

The webcast replay will be archived on Avadel's website for 90 days following the event.

What financial information will AVDL discuss in its January 8, 2025 update?

AVDL will discuss preliminary unaudited financial results for both the fourth quarter and full year ended December 31, 2024, along with a corporate update.